Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Neoplasia with IDH1 Mutation
Description for laymen
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Neoplasia with IDH1 Mutation
JSON Data
{
"short_title": "PIVOT",
"data_mode": "910",
"data_mode_number": "000000069",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2023-509055-14-00",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Prospektive Bewertung der Ivosidenib-Erhaltung nach allogener Stammzelltransplantation bei Patienten mit akuter myeloischer Leuk\u00e4mie oder myelodysplastischer Neoplasie mit IDH1-Mutation",
"description_laie_en": "Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Neoplasia with IDH1 Mutation",
"description_expert_de": "Prospektive Bewertung der Ivosidenib-Erhaltung nach allogener Stammzelltransplantation bei Patienten mit akuter myeloischer Leuk\u00e4mie oder myelodysplastischer Neoplasie mit IDH1-Mutation",
"description_expert_en": "Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Neoplasia with IDH1 Mutation",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 30
}
